{"id":"dapa","rwe":[{"pmid":"41874429","year":"2026","title":"Novel protein biomarkers for risk stratification and personalized medicine.","finding":"","journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","studyType":"Clinical Study"},{"pmid":"41870543","year":"2026","title":"Dapagliflozin attenuates myocardial fibrosis after myocardial infarction through regulating Lnc-Ang362/miR-200b-3p.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"41866889","year":"2026","title":"Dapagliflozin and Crocin Ameliorate DOX-Induced Cardiotoxicity in Rats via Activating the Nrf-2/HO-1/NQO1 Pathway: A Comparative Study.","finding":"","journal":"Immunopharmacology and immunotoxicology","studyType":"Clinical Study"},{"pmid":"41856972","year":"2026","title":"Dapagliflozin regulates chondrocyte homeostasis and protects against osteoarthritis via targets AMPKα and SGLT2.","finding":"","journal":"Cell death discovery","studyType":"Clinical Study"},{"pmid":"41847669","year":"2025","title":"Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI).","finding":"","journal":"Journal of the Saudi Heart Association","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"LOE Approaching","category":"status"},{"label":"Astrazeneca Ab","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Diarrhea","drugRate":"9.6%","severity":"common","organSystem":""},{"effect":"Nausea/Vomiting","drugRate":"6.5%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Renal impairment","drugRate":"0.7%","severity":"serious"},{"effect":"Increased blood creatinine","drugRate":"0.2%","severity":"serious"},{"effect":"Decreased renal creatinine clearance","drugRate":"0.2%","severity":"serious"},{"effect":"Urinary tract infection","drugRate":"0.2%","severity":"serious"}]},"trials":[],"aliases":["Farxiga 10 mg"],"company":"Astrazeneca Ab","patents":[{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"May 26, 2030","useCode":"U-1522","territory":"US","drugProduct":false,"patentNumber":"8685934","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Aug 18, 2026","useCode":"U-2139","territory":"US","drugProduct":false,"patentNumber":"8906851","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Aug 18, 2026","useCode":"U-2213","territory":"US","drugProduct":false,"patentNumber":"8329648","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Expired","expires":"Oct 4, 2025","useCode":"U-493","territory":"US","drugProduct":true,"patentNumber":"6515117","drugSubstance":true},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Mar 21, 2028","useCode":"U-2139","territory":"US","drugProduct":false,"patentNumber":"8361972","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Jun 20, 2027","useCode":"U-493","territory":"US","drugProduct":true,"patentNumber":"8501698","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Mar 9, 2040","useCode":"U-3127","territory":"US","drugProduct":false,"patentNumber":"10973836","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Apr 1, 2041","useCode":"U-4140","territory":"US","drugProduct":false,"patentNumber":"12213988","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Apr 1, 2041","useCode":"U-4140","territory":"US","drugProduct":false,"patentNumber":"12409186","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Jul 18, 2039","useCode":"U-4346","territory":"US","drugProduct":false,"patentNumber":"12472194","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Jul 18, 2039","useCode":"U-3766","territory":"US","drugProduct":false,"patentNumber":"11826376","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Mar 9, 2040","useCode":"U-3825","territory":"US","drugProduct":false,"patentNumber":"11903955","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Aug 19, 2028","useCode":"","territory":"US","drugProduct":true,"patentNumber":"7851502","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Jan 18, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8721615","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Mar 21, 2028","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8221786","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Dec 16, 2029","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7919598","drugSubstance":true},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Mar 21, 2028","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8716251","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Sep 21, 2028","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8221786*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Apr 4, 2026","useCode":"","territory":"US","drugProduct":false,"patentNumber":"6515117*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Dec 20, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8501698*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Sep 21, 2028","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8361972*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Feb 19, 2029","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7851502*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Jun 16, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7919598*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Sep 21, 2028","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8716251*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Nov 26, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8685934*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Feb 18, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8329648*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Jul 18, 2030","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8721615*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Feb 18, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8906851*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Jan 18, 2040","useCode":"","territory":"US","drugProduct":false,"patentNumber":"12472194*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Jan 18, 2040","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11826376*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Sep 9, 2040","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11903955*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Sep 9, 2040","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10973836*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Oct 1, 2041","useCode":"","territory":"US","drugProduct":false,"patentNumber":"12409186*PED","drugSubstance":false},{"applNo":"N202293","source":"FDA Orange Book","status":"Active","expires":"Oct 1, 2041","useCode":"","territory":"US","drugProduct":false,"patentNumber":"12213988*PED","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DAPA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:36:21.303391+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:36:21.303300+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:36:26.805038+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DAPA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:36:27.003058+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4281478/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:36:27.693741+00:00"}},"allNames":["dapa"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Woman's to Astrazeneca Ab"},{"date":"2025-10-04","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 6515117 expires"},{"date":"2026-05-08","type":"negative","source":"FDA Orange Book","milestone":"M-298 exclusivity expires"},{"date":"2026-11-08","type":"negative","source":"FDA Orange Book","milestone":"Pediatric exclusivity expires"},{"date":"2027-06-12","type":"negative","source":"FDA Orange Book","milestone":"NPP exclusivity expires"},{"date":"2027-12-12","type":"negative","source":"FDA Orange Book","milestone":"Pediatric exclusivity expires"},{"date":"2029-12-16","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7919598 expires"}],"approvals":[],"ecosystem":[],"mechanism":{"target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Unfortunately, there is not enough information available to provide a technical detail summary of dapa's mechanism of action."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=dapa","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dapa","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:18:11.869490","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:36:29.321142+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"exclusivity":[{"code":"M-298","date":"May 8, 2026"},{"code":"NPP","date":"Jun 12, 2027"},{"code":"M-298","date":"May 8, 2026"},{"code":"NPP","date":"Jun 12, 2027"},{"code":"PED","date":"Nov 8, 2026"},{"code":"PED","date":"Nov 8, 2026"},{"code":"PED","date":"Dec 12, 2027"},{"code":"PED","date":"Dec 12, 2027"}],"genericName":"dapa","indications":{"approved":[{"name":"Chronic heart failure","diseaseId":"chronic-heart-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic kidney disease","diseaseId":"chronic-kidney-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diabetes mellitus type 1","diseaseId":"diabetes-mellitus-type-1","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diabetes mellitus type 2","diseaseId":"diabetes-mellitus-type-2","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Astrazeneca Ab","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07120828","phase":"PHASE4","title":"The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity","status":"COMPLETED","sponsor":"Erbil Polytechnic University","startDate":"2025-07-15","conditions":["Type 2 Diabetes","Obese Diabetics","Obese Patients (BMI ≥ 30 kg/m²)"],"enrollment":260,"completionDate":"2026-03-15"},{"nctId":"NCT06785116","phase":"PHASE4","title":"A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-03-02","conditions":["Gestational Hypertension","Hypertension in Pregnancy","Pre-Eclampsia","Superimposed Pre-Eclampsia","Cardiovascular Complication"],"enrollment":200,"completionDate":"2028-08"},{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":["Diabetes Mellitus","Liver Transplant; Complications"],"enrollment":100,"completionDate":"2026-02-27"},{"nctId":"NCT07157735","phase":"PHASE2","title":"A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease","status":"RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2026-02-02","conditions":["Parkinson Disease"],"enrollment":36,"completionDate":"2028-02"},{"nctId":"NCT07025629","phase":"PHASE3","title":"Dapagliflozin for Cardio-renal Protection After ICU Discharge","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-02","conditions":["Heart Failure and Chronic Kidney Disease Post-ICU"],"enrollment":600,"completionDate":"2029-01-15"},{"nctId":"NCT06907251","phase":"PHASE3","title":"Dapagliflozin for Long COVID Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2026-04-01","conditions":["COVID - 19","Long COVID Syndrome","SARS CoV-2"],"enrollment":192,"completionDate":"2029-06-30"},{"nctId":"NCT06812429","phase":"EARLY_PHASE1","title":"Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2024-05-08","conditions":["Inflammation"],"enrollment":6,"completionDate":"2025-04-05"},{"nctId":"NCT06954090","phase":"PHASE4","title":"Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study","status":"ENROLLING_BY_INVITATION","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2025-11-20","conditions":["Type 2 DM","Type 2 DM /Diabetic Nephropathy","Albuminuria"],"enrollment":50,"completionDate":"2027-05-31"},{"nctId":"NCT06778330","phase":"NA","title":"The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-01-20","conditions":["Heart Failure NYHA Class II"],"enrollment":100,"completionDate":"2025-08-01"},{"nctId":"NCT06922656","phase":"PHASE4","title":"Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2025-09-15","conditions":["Type 1 Diabetes"],"enrollment":60,"completionDate":"2027-01-15"},{"nctId":"NCT07076615","phase":"PHASE4","title":"The Effect of Dapagliflozin on Patients With Cardiomyopathy","status":"RECRUITING","sponsor":"May Mohamed Abdalla","startDate":"2025-08","conditions":["Acute Decompensated Heart Failure (ADHF)"],"enrollment":100,"completionDate":"2026-05"},{"nctId":"NCT07082114","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-07-14","conditions":["Type 2 Diabetes"],"enrollment":800,"completionDate":"2027-05-17"},{"nctId":"NCT07077525","phase":"PHASE4","title":"Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-06-01","conditions":["Type 2 Diabetes"],"enrollment":196,"completionDate":"2024-08-31"},{"nctId":"NCT05981391","phase":"","title":"Neurobiological Similarities of Tinnitus and PTSD","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-02-04","conditions":["Posttraumatic Stress Disorder","Tinnitus"],"enrollment":64,"completionDate":"2024-11-01"},{"nctId":"NCT04363697","phase":"PHASE4","title":"Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-09-24","conditions":["Acute Heart Failure","Heart Failure"],"enrollment":2401,"completionDate":"2025-06-02"},{"nctId":"NCT04591639","phase":"NA","title":"The DAPA-MEMRI Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-08-19","conditions":["Heart Failure","Diabetic Cardiomyopathies"],"enrollment":160,"completionDate":"2028-07-28"},{"nctId":"NCT07020377","phase":"PHASE1,PHASE2","title":"Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amira Bisher,PhD","startDate":"2024-01-15","conditions":["Diabetes Mellitus","Non Alcholic Fatty Liver Disease"],"enrollment":60,"completionDate":"2025-12-30"},{"nctId":"NCT06626737","phase":"PHASE2","title":"Dapagliflozin in Allo-HCT for aGVHD","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-04-26","conditions":["Graft-versus-host Disease (GVHD)"],"enrollment":72,"completionDate":"2026-12-31"},{"nctId":"NCT06350123","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-05-01","conditions":["Chronic Kidney Disease"],"enrollment":324,"completionDate":"2025-05-09"},{"nctId":"NCT06897605","phase":"PHASE2","title":"Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-01","conditions":["Chronic Kidney Disease(CKD)","Anemia, Kidney Disease, Chronic"],"enrollment":80,"completionDate":"2025-10"},{"nctId":"NCT05541484","phase":"PHASE4","title":"Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2022-10-14","conditions":["Diabetes Mellitus, Type 1"],"enrollment":21,"completionDate":"2023-12-23"},{"nctId":"NCT06820567","phase":"PHASE3","title":"Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-03-01","conditions":["Chronic Kidney Diseases","Diabetes Type 2"],"enrollment":210,"completionDate":"2027-05-01"},{"nctId":"NCT06813222","phase":"","title":"Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Damanhour University","startDate":"2021-04-01","conditions":["Anemia","CKD"],"enrollment":100,"completionDate":"2025-03-01"},{"nctId":"NCT06759077","phase":"PHASE3","title":"Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-12-28","conditions":["Kidney Diseases"],"enrollment":126,"completionDate":"2025-12-28"},{"nctId":"NCT06759909","phase":"PHASE1","title":"Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-01-03","conditions":["Dapagliflozin (Forxiga)","Atrial Fibrillation (AF)"],"enrollment":100,"completionDate":"2028-12-22"},{"nctId":"NCT05792540","phase":"PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-06-06","conditions":["Depressive Disorder"],"enrollment":75,"completionDate":"2024-12-20"},{"nctId":"NCT06748105","phase":"PHASE2","title":"Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lauro Fabián Amador Medina","startDate":"2024-12-01","conditions":["Dapagliflozin (Forxiga)","Hyperglycaemia","Glucocorticoid"],"enrollment":38,"completionDate":"2025-12-01"},{"nctId":"NCT06721442","phase":"PHASE4","title":"Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study","status":"COMPLETED","sponsor":"Beneficência Portuguesa de São Paulo","startDate":"2023-01-10","conditions":["Arrhythmias, Cardiac","Diabetes Mellitus"],"enrollment":174,"completionDate":"2024-07-10"},{"nctId":"NCT04792190","phase":"PHASE4","title":"Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2021-07-27","conditions":["Atrial Fibrillation"],"enrollment":25,"completionDate":"2023-06-30"},{"nctId":"NCT04445714","phase":"PHASE4","title":"To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-07","conditions":["Type 2 Diabetes Mellitus"],"enrollment":196,"completionDate":"2023-03-14"},{"nctId":"NCT06442280","phase":"PHASE4","title":"SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF","status":"NOT_YET_RECRUITING","sponsor":"University of Palermo","startDate":"2024-06","conditions":["Heart Failure Acute","Diabetes Type 2","Heart Failure With Reduced Ejection Fraction","Heart Failure With Preserved Ejection Fraction"],"enrollment":544,"completionDate":"2026-03-30"},{"nctId":"NCT05174052","phase":"PHASE3","title":"Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2022-06-01","conditions":["Diabetes Mellitus","Atrial Fibrillation"],"enrollment":28,"completionDate":"2025-04-01"},{"nctId":"NCT05759000","phase":"","title":"Dapa Acute Heart Failure Study","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2023-04-09","conditions":["Heart Failure"],"enrollment":100,"completionDate":"2025-12-09"},{"nctId":"NCT04956809","phase":"PHASE2","title":"Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-10-22","conditions":["HFrEF"],"enrollment":3,"completionDate":"2023-06-01"},{"nctId":"NCT04400760","phase":"PHASE2,PHASE3","title":"The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.","status":"COMPLETED","sponsor":"The University of The West Indies","startDate":"2020-05-01","conditions":["Platelet Dysfunction"],"enrollment":40,"completionDate":"2022-06-30"},{"nctId":"NCT06117137","phase":"PHASE3","title":"The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-11-15","conditions":["Fatty Liver, Nonalcoholic"],"enrollment":150,"completionDate":"2024-10"},{"nctId":"NCT04730947","phase":"PHASE2","title":"Dapagliflozin (DAPA) Effects in HFpEF","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-02-24","conditions":["Heart Failure With Preserved Ejection Fraction"],"enrollment":38,"completionDate":"2022-11-17"},{"nctId":"NCT06009874","phase":"NA","title":"Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI","status":"RECRUITING","sponsor":"Mohammad Hussien Tantawy Soliman","startDate":"2023-10","conditions":["Myocardial Infarction"],"enrollment":80,"completionDate":"2026-08"},{"nctId":"NCT05406505","phase":"PHASE2,PHASE3","title":"Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-04-25","conditions":["Acute Heart Failure"],"enrollment":87,"completionDate":"2023-07-01"},{"nctId":"NCT04882813","phase":"","title":"Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-13","conditions":["Chronic Kidney Disease"],"enrollment":87727,"completionDate":"2021-06-11"},{"nctId":"NCT04717986","phase":"NA","title":"Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2021-01-26","conditions":["Acute Myocardial Infarction","Cardiovascular Morbidity","Heart Failure","Angina, Unstable"],"enrollment":188,"completionDate":"2023-06-20"},{"nctId":"NCT03660683","phase":"PHASE4","title":"Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Sabyasachi Sen","startDate":"2018-10-22","conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases"],"enrollment":15,"completionDate":"2021-12-10"},{"nctId":"NCT05717257","phase":"PHASE4","title":"Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)","status":"UNKNOWN","sponsor":"Monaldi Hospital","startDate":"2022-08-01","conditions":["Dapagliflozin Adverse Reaction","Efficacy","Systemic Right Ventricle"],"enrollment":50,"completionDate":"2024-08"},{"nctId":"NCT05141552","phase":"NA","title":"The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-01-03","conditions":["Hemodialysis Complication"],"enrollment":20,"completionDate":"2022-07-31"},{"nctId":"NCT03624803","phase":"","title":"DAPA - Egypt Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-03-09","conditions":["Type-2 Diabetes"],"enrollment":200,"completionDate":"2020-03-30"},{"nctId":"NCT02635386","phase":"PHASE3","title":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Woman's","startDate":"2016-03-22","conditions":["Polycystic Ovary Syndrome","Obesity"],"enrollment":119,"completionDate":"2020-10-09"},{"nctId":"NCT01974726","phase":"NA","title":"Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2013-10","conditions":["Eustachian Tube Dysfunction"],"enrollment":95,"completionDate":"2019-06-27"},{"nctId":"NCT04242758","phase":"PHASE4","title":"Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2019-06-04","conditions":["Renal Function Disorder","Glucose Metabolism Disorders"],"enrollment":30,"completionDate":"2020-04-01"},{"nctId":"NCT04183361","phase":"","title":"ABR Characteristics and Salivary Cortisone Concentration in Noise-exposed Workers","status":"UNKNOWN","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2019-11-01","conditions":["Sensorineural Hearing Loss","Noise Induced Hearing Loss","Auditory Nerve; Lesion"],"enrollment":100,"completionDate":"2020-11-01"},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":56,"completionDate":"2018-06-30"},{"nctId":"NCT02956811","phase":"PHASE4","title":"Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2017-02-14","conditions":["Type 2 Diabetes","Left Ventricular Hypertrophy"],"enrollment":66,"completionDate":"2019-04-02"},{"nctId":"NCT02338193","phase":"PHASE3","title":"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women","status":"COMPLETED","sponsor":"Woman's","startDate":"2015-09-22","conditions":["Diabetes Prevention in Women After GDM Who Are at High-risk"],"enrollment":69,"completionDate":"2019-03-13"},{"nctId":"NCT02551874","phase":"PHASE3","title":"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-20","conditions":["Type 2 Diabetes Mellitus"],"enrollment":650,"completionDate":"2017-11-10"},{"nctId":"NCT02558270","phase":"PHASE2","title":"Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2016-06","conditions":["Type 2 Diabetes","Metabolically Healthy Controls"],"enrollment":20,"completionDate":"2018-06"},{"nctId":"NCT02060201","phase":"PHASE1","title":"Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-02","conditions":["Type 2 Diabetes Mellitus"],"enrollment":72,"completionDate":"2014-05"},{"nctId":"NCT01877889","phase":"PHASE1","title":"A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-07","conditions":["Healthy"],"enrollment":60,"completionDate":"2014-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL4281478"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Woman's","relationship":"Original Developer"},{"period":"present","companyName":"Astrazeneca Ab","relationship":"Current Owner"}],"publicationCount":1363,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"originalDeveloper":"Woman's","recentPublications":[{"date":"2026 Mar 24","pmid":"41874429","title":"Novel protein biomarkers for risk stratification and personalized medicine.","journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"date":"2026 Mar 23","pmid":"41870543","title":"Dapagliflozin attenuates myocardial fibrosis after myocardial infarction through regulating Lnc-Ang362/miR-200b-3p.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2026 Mar 23","pmid":"41866889","title":"Dapagliflozin and Crocin Ameliorate DOX-Induced Cardiotoxicity in Rats via Activating the Nrf-2/HO-1/NQO1 Pathway: A Comparative Study.","journal":"Immunopharmacology and immunotoxicology"},{"date":"2026 Mar 19","pmid":"41856972","title":"Dapagliflozin regulates chondrocyte homeostasis and protects against osteoarthritis via targets AMPKα and SGLT2.","journal":"Cell death discovery"},{"date":"2025","pmid":"41847669","title":"Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI).","journal":"Journal of the Saudi Heart Association"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","brandName":"DAPA","companyName":"Astrazeneca Ab","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:36:29.321142+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}